Viscient will turn its attention to 3D bioprinting lung tissue for infectivity research to assist global efforts to combat SARS-CoV-2, the novel coronavirus that causes COVID-19.
Organovo failed to receive a majority of stockholder votes in favor of its merger, and 47 million shares cast votes against the Board’s recommendation to allow adjournment of the purported special meeting.
Organovo did not follow SEC guidance in changing the location of its special meeting to hold the merger vote, therefore validity of the adjournment is in question.
Given world events and the need for unity and focus of efforts at this time, Keith Murphy, founder of Viscient Biosciences and Organovo, calls for pause in Organovo merger attempt.